Early Assets Excite At Novartis R&D Day
430 drug discovery projects trimmed to 325
Executive Summary
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.